Discover how the experimental drug donanemab can slow early Alzheimer's disease progression by 60%. Learn about the potential benefits and side effects.
A new drug called donanemab has shown promising results in slowing down cognitive decline in early-stage Alzheimer's patients. Read about its potential impact and pending regulatory approval.
Discover how the experimental drug donanemab can slow early Alzheimer's disease progression by 60%. Learn about the potential benefits and side effects.
Discover Eli Lilly's groundbreaking Alzheimer's drug, donanemab, offering hope for treating dementia. Promising results in slowing down memory decline and improving day-to-day activities.
Eli Lilly's donanemab drug shows promising results in slowing Alzheimer's progression by 60% for early-stage patients, but with notable side effects. Read more.